Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 12/20 | 0.72 |
| ▸ | CA12 | O43570 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
| ▸ | CA4 | P22748 | 1/20 | 0.55 |
| ▸ | CA6 | P23280 | 1/20 | 0.55 |
| ▸ | CA5A | P35218 | 1/20 | 0.55 |
| ▸ | CA7 | P43166 | 1/20 | 0.55 |
| ▸ | CA9 | Q16790 | 1/20 | 0.55 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.55 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.55 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.50 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.50 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL96651 | 0.94 | PTGS2 (0.68) | PTGS2CA12CA1CA2CA4 | |
| SCHEMBL8485289 | 0.89 | PTGS2 (0.70) | PTGS2 | |
| SCHEMBL8655486 | 0.84 | PTGS2 (1.00) | PTGS2 | |
| SCHEMBL8974092 | 0.84 | PTGS2 (0.63) | PTGS2CA12CA1CA2CA4 | |
| SCHEMBL2025954 | 0.82 | FYN (0.57) | PTGS2CA12CA2CA9ADAMTS4 | |
| SCHEMBL5399297 | 0.82 | PTGES2 (0.53) | PTGS2ADAMTS4 | |
| SCHEMBL10300269 | 0.82 | PTGS2 (0.62) | PTGS2CA12CA2CA9ENPP2 | |
| SCHEMBL7677302 | 0.82 | PTGS2 (0.62) | PTGS2CA12CA2CA9ENPP2 | |
| SCHEMBL13634219 | 0.81 | UCHL1 (0.59) | PTGS2CA2ENPP2PTGDR2 | |
| SCHEMBL11296178 | 0.81 | CA1 (0.57) | PTGS2CA12CA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7141596-B2 | Inhibitors of proteins that bind phosphorylated molecules | INCYTE CORPORATION (US) | 2006-11-28 | — | — | US | disclosed |
| US-20050272778-A1 | Inhibitors of proteins that bind phosphorylated molecules | INCYTE CORPORATION | 2005-12-08 | — | — | US | disclosed |
| WO-2005035551-A2 | INHIBITORS OF PROTEINS THAT BIND PHOSPHORYLATED MOLECULES | INCYTE CORPORATION (US) | 2005-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272778-A1 | Inhibitors of proteins that bind phosphorylated molecules | PPP3CA, PPP5C, PPM1A | PTGS2 4347/4885CA12 4677/4885CA1 4373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.